148 related articles for article (PubMed ID: 36090728)
1. Effectiveness of infliximab biosimilars in the treatment of moderate to severe chronic plaque psoriasis: experience of real-world data from the register of the program "Treatment of moderate and severe forms of plaque psoriasis (B.47)" of the National Health Fund in Poland.
Owczarek W; Walecka I; Nowakowska A; Ciechanowicz P; Reich A; Lesiak A; Borkowska E; Śliwczyñski A; Narbutt J
Postepy Dermatol Alergol; 2022 Aug; 39(4):723-728. PubMed ID: 36090728
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of adalimumab versus ustekinumab in the treatment of severe chronic plaque psoriasis: The results based on data from the program "treatment of moderate and severe forms of plaque psoriasis (B.47)" of the National Health Fund in Poland.
Owczarek W; Nowakowska A; Walecka I; Ciechanowicz P; Reich A; Lesiak A; Borkowska E; Śliwczyński A; Narbutt J
Dermatol Ther; 2022 Jun; 35(6):e15481. PubMed ID: 35363386
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality-of-life improvements during 98 weeks of infliximab therapy in patients with plaque-type psoriasis in real-world practice.
Shear NH; Hartmann M; Toledo-Bahena ME; Gilbert M; Katsambas A; Yao R; Popmihajlov Z
Qual Life Res; 2016 Aug; 25(8):2031-40. PubMed ID: 26869477
[TBL] [Abstract][Full Text] [Related]
4. Real world experience of brodalumab treatment in patients with moderate-to-severe plaque psoriasis in the Greek population: Results from an interim analysis of the BrIDGE study.
Rigopoulos D; Angelakopoulos C; Apalla Z; Georgiou S; Delli F; Drosos A; Zafiriou E; Katsantonis J; Lazaridou E; Panagakis P; Papadavid E; Papakonstantis M; Roussaki-Schulze AV; Sotiriou E; Anastasiadis G; Tampouratzi E; Chasapi V; Sfaelos K; Ioannides D;
Dermatol Ther; 2022 Dec; 35(12):e15886. PubMed ID: 36184757
[TBL] [Abstract][Full Text] [Related]
5. Real-life Efficacy and Safety of Biosimilar Adalimumab (ZRC-3197) in Patients with Plaque Psoriasis: A Tertiary Care Center Experience.
Chopra A; Mitra D; Agarwal R; Saraswat N; Chemburkar P; Sharma L
Indian Dermatol Online J; 2020; 11(2):182-186. PubMed ID: 32477976
[TBL] [Abstract][Full Text] [Related]
6. The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis.
Dapavo P; Vujic I; Fierro MT; Quaglino P; Sanlorenzo M
J Am Acad Dermatol; 2016 Oct; 75(4):736-739. PubMed ID: 27473452
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
[TBL] [Abstract][Full Text] [Related]
8. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.
Antoniou C; Stefanaki I; Stratigos A; Moustou E; Vergou T; Stavropoulos P; Avgerinou G; Rigopoulos D; Katsambas AD
Br J Dermatol; 2010 May; 162(5):1117-23. PubMed ID: 19906069
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice.
Shear NH; Hartmann M; Toledo-Bahena M; Katsambas A; Connors L; Chang Q; Yao R; Nograles K; Popmihajlov Z;
Br J Dermatol; 2014 Sep; 171(3):631-41. PubMed ID: 24673357
[TBL] [Abstract][Full Text] [Related]
10. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
Spuls PI; Hooft L
Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
[TBL] [Abstract][Full Text] [Related]
11. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
Torii H; Nakagawa H;
J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
[TBL] [Abstract][Full Text] [Related]
12. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.
Reich K; Nestle FO; Papp K; Ortonne JP; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE;
Lancet; 2005 Oct 15-21; 366(9494):1367-74. PubMed ID: 16226614
[TBL] [Abstract][Full Text] [Related]
13. A multicenter, prospective, observational study examining the impact of risk factors, such as BMI and waist circumference, on quality of life improvement and clinical response in moderate-to-severe plaque-type psoriasis patients treated with infliximab in routine care settings of Greece.
Petridis A; Panagakis P; Moustou E; Vergou T; Kallidis P; Mandekou-Lefaki I; Chaidemenos G; Sotiriadis D; Alexopoulou G; Haratsis Y; Antoniou C
J Eur Acad Dermatol Venereol; 2018 May; 32(5):768-775. PubMed ID: 29356149
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of apremilast in the treatment of plaques psoriasis: A real-world, single-center experience.
Radi G; Campanati A; Diotallevi F; Rizzetto G; Martina E; Bobyr I; Giannoni M; Offidani A
Dermatol Ther; 2021 Nov; 34(6):e15179. PubMed ID: 34704350
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis).
Gargiulo L; Narcisi A; Ibba L; Balato A; Bianchi L; Brianti P; Buononato D; Burlando M; Caldarola G; Campanati A; Campione E; Carrera CG; Carugno A; Cristaudo A; Cusano F; Dapavo P; Dattola A; De Simone C; Gaiani FM; Gisondi P; Giunta A; Loconsole F; Maione V; Mortato E; Marzano AV; Maurelli M; Megna M; Mercuri SR; Offidani A; Orsini D; Parodi A; Pellacani G; Potestio L; Quaglino P; Richetta AG; Romano F; Sena P; Venturini M; Malagoli P; Costanzo A
Front Med (Lausanne); 2023; 10():1243843. PubMed ID: 37614958
[TBL] [Abstract][Full Text] [Related]
16. Ixekizumab treatment in patients with moderate-to-severe plaque psoriasis in a real-world clinical setting.
Demirel Öğüt N; Koç Yıldırım S; Erbağcı E; Hapa FA
J Cosmet Dermatol; 2022 Nov; 21(11):6215-6224. PubMed ID: 35801372
[TBL] [Abstract][Full Text] [Related]
17. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB
J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
[TBL] [Abstract][Full Text] [Related]
18. Clinical evidence on the use of brodalumab for the treatment of psoriasis in Greece: Experience from clinical practice of four tertiary hospitals.
Tampouratzi E; Papakonstantis M; Katsantonis J; Sidiropoulos T; Delli F; Efthymiadis K; Sfaelos K; Christodoulou A; Chasapi V; Panagakis P
Dermatol Ther; 2022 Jul; 35(7):e15532. PubMed ID: 35451147
[TBL] [Abstract][Full Text] [Related]
19. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
[TBL] [Abstract][Full Text] [Related]
20. Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study.
Martorell A; Santos-Alarcón S; Sahuquillo-Torralba A; Rivera-Díaz R; Belinchón-Romero I; Ruiz-Genao D; Romero-Maté A; Ruiz-Villaverde R; Ferran-Farrés M; Gallardo-Hernández F; Almenara-Blasco M; Suarez-Perez JA; González-Cantero Á; Martínez-Lorenzo E; Fernández-Armenteros JM; Del Alcázar-Viladomiu E; García-Latasa J; Rocamora-Durant V; Ara-Martín M; Mateu-Puchades A; Llamas-Velasco M; Vilarrasa E; Velasco-Pastor M; De la Cueva P; Carrascosa JM; Magdaleno-Tapial J
Actas Dermosifiliogr; 2024 Mar; ():. PubMed ID: 38452889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]